Xinruibai (pegfilgrastim biosimilar) / Qilu Pharma - LARVOL DELTA

Telpegfilgrastim for chemotherapy-induced neutropenia in patients with non-small cell lung cancer: a multicentre, randomized, phase 3 study. (PubMed, BMC Cancer) - P3 | "This study demonstrated that telpegfilgrastim 2 mg or 33 μg/kg was non-inferior to rhG-CSF (Topneuter®) and PEG-rhG-CSF (Xinruibai®) for the management of CIN in patients with NSCLC. In particular, a 2 mg fixed dose of telpegfilgrastim presents a more convenient administration option."

Clinical • Journal • P3 data • Chemotherapy-Induced Neutropenia • Febrile Neutropenia • Hematological Disorders • Lung Cancer • Neutropenia • Non Small Cell Lung Cancer • Oncology • Solid Tumor

A REAL WORLD STUDY OF PEG-RHG-CSF ON HEMATOPOIETIC RECOVERY AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (EHA 2022) - "PEG-rhG-CSF(xinruibai) was used in the hematopoietic recovery and given in the dose of 100μg/kg on day +1and day +8...There was no significant difference in the incidence of fever and duration of fever between two groups(P＞0.05)． Conclusion The efficacy of PEG-rhG-CSF in promoting hematopoietic recovery after allogeneic hematopoietic stem cell transplantation is good , without severe untoward effects. There is no obvious difference in hematopoietic recovery in Aplastic Anemia and hematological malignancy."

Clinical • Real-world evidence • Anemia • Aplastic Anemia • Bone Marrow Transplantation • Hematological Disorders • Hematological Malignancies • Infectious Disease • Oncology • Transplantation